Patient characteristics and survival outcomes of lenalidomide exposed non-refractory vs. lenalidomide refractory multiple myeloma patients in the HONEUR Federated Data Network
Abstract
The increased use of Lenalidomide (Len) regimens in earlier lines of treatment has led to a higher number of Len refractory patients (Moreau P, Blood Cancer J 2019). Description of patients who have become refractory to Len vs. those exposed but did not become refractory is limited.